Replies to post #1395 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

"The 105th event is irrelevant when it happened, who cares?

Based on the above the minimum composite rate reached so far is pretty solid, and if Avastin is behaving like historical (that is the only big assumption I am making), then VBL111 is already showing an improvement vs Avastin monotherapry. "

Who cares? LOL. Backtracking now are we ...? If your numbers are solid then you would know this. Interim was going to be a big event until the FDA canceled it. But for you, it's, "Who cares?" Keep making up these idiotic assumptions ... can't wait for when the final numbers come out.

By the way, hope you haven't mistaken VB-111 for VBL111. Being that you're experienced and all ...

[mantoo123]

As far as I know, there have been at least 10 studies involving Avastin. Thus, it is reasonable to assume that Avastin will behave similar to past in the GLOBE study as well. Note that there was some variation in OS results with Avastin between studies.

In any case, given that Kaplan-Meier curvers are all about precise data, without knowing the enrollment dates with relative precision all predictions about top-line result announcement date are moot.

We will know the results when they are announced and not before.